AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

A Phase I, Open-Label, Multi-centre Study to Assess the Safety, Tolerability and Pharmacokinetics of a Solid Oral Dosage Formulation (Capsule) of AZD6244 in Patients With Advanced Solid Malignancies

The primary purpose of the study is to assess the safety, tolerability and pharmacokinetics of a capsule of AZD6244 in participants with advanced solid malignancies

Inclusion Criteria:

• cancer which is refractory to standard therapies
• World Health Organization (WHO) performance status 0 to 2
• evidence of post-menopausal status or negative pregnancy test

Exclusion Criteria:

• Radiotherapy/chemotherapy within 21 days prior to entry
• brain metastases/spinal cord compression unless stable off steroids/anticonvulsants
• evidence of severe/uncontrolled systemic disease
• participated in an investigational drug study within 30 days